The FDA approved fosdenopterin (Nulibry) — the first specific treatment for the rare metabolic disorder molybdenum cofactor deficiency type A.
Hospitalized COVID-19 patients with low free T3 levels saw significantly higher rates of mortality, mechanical ventilation, and ICU admission. (Endocrine Practice)
Almost a quarter of patients with kidney stone disease also had osteoporosis or a fracture, according to a study of over 500,000 people. (Journal of Bone and Mineral Research)
In related news, women with primary ovarian insufficiency who experience early menopause have a higher risk for osteoporosis. “This study … underscores the importance of the use of hormone therapy at least until the natural age of menopause in order to reduce the significant morbidity and mortality associated with osteoporotic fractures,” commented Stephanie Faubion, MD, North American Menopause Society medical director. (Menopause)
A nurse at the Yale Reproductive Endocrinology and Infertility clinic in Connecticut pleaded guilty for taking fentanyl intended for the fertility clinic patients. (NBC Connecticut)
The American Thyroid Association, British Thyroid Association, and European Thyroid Association issued a joint consensus statement to guide future clinical trials on LT4/LT3 combination therapy. (Thyroid)
The Endocrine Society announced Kate Fryer as its next chief executive officer.
A New York dietary supplement manufacturer was ordered by a federal judge to immediately stop making and distributing dietary supplements, FDA announced.
Source: MedicalNewsToday.com
